MEMaxim Sergeevich Eliseev

Maxim Sergeevich Eliseev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maxim Sergeevich Eliseev has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunological features of hyperuricemia and gout phenotypes

    by M. S. Eliseev, M. N. Chikina, Ya. I. Kuzmina, S. I. Glukhova, М. С. Елисеев, М. Н. Чикина, Я. И. Кузьмина, С. И. Глухова

    Current phenotypic classification of hyperuricemia (HU) and gout is based on the presence/absence of monosodium urate (MSU) crystals, clinical signs of gout, and tophi in individuals with elevated uric acid (UA) levels. It is hypothesized that the severity of subclinical inflammation may differ for HU and gout phenotypes. Aim: To test the hypothesis of increasing systemic inflammation intensity with HU progresses in patients within the proposed phenotypic classification. Material and Methods. 220 patients with HU (UA > 360 μmol/L) over 18 years of age were examined and divided into the following phenotypes: asymptomatic HU (AHU); AHU with MSU crystals (verified by ultrasound or synovial fluid analysis) (AHU+crystals); intermittent gout (G); tophaceous gout (G+tophi). Comparative characteristics of the groups included an assessment of the frequency of comorbidities, metabolic disorders, and the main laboratory parameters. Results. According to phenotyping results, the group of patients with AHU consisted of 40 people (18.2%), AHU+crystals – 26 (11.8%), G – 111 (50.5%), G+tophi – 43 (19.5%). The age in the groups was comparable (p = 0.5). An increase in the incidence of arterial hypertension and nephrolithiasis was revealed in the series AHU – AHU+crystals – G – G+tophi ( p = 0.0006 and p = 0.00006, respectively). There was a statistically significant sequential increase in the median value of IL-6 in the groups from AHU to G+tophi ( p = 0.0001). Also, in patients with AHU without MSU crystals, the average serum level of IL-18 was lower than that in the G+tophi group ( p = 0.01). The level of highly sensitive C-reactive protein (hsCRP) was statistically significantly different in patients with AHU compared to patients with G and G+ tophi ( p = 0.04 in both cases). Correlation analysis revealed a weak positive association between UA and IL-6 levels ( r = 0.14, p < 0.05) and UA and hsCRP levels ( r = 0.26, p < 0.05) in the general group ( n = 220). A weak correlation between IL-6 and UA levels was also observed within each group ( p < 0.05 in all cases). A moderate positive correlation was also found between UA and IL-8 levels ( r = 0.36, p < 0.05) in patients in the AHU group ( n = 40). Conclusions. The severity of chronic inflammation in HU is associated with the level of serum UA in the blood and the presence of MSU crystals, and increases during the progression from AHU to chronic tophaceous gout.

  • Open Access

    Long-term pharmacotherapy for calcium pyrophosphate deposition disease: results of an observational study

    by M. S. Eliseev, A. M. Lila

    Only a few studies have addressed the treatment of calcium pyrophosphate deposition disease (CPPD). Objective: to determine the frequency of prescribing long-term courses of pharmacotherapy, as well as individual drugs and their combinations, to patients with different CPPD phenotypes. Material and methods . This retrospective observational study included adult patients with symptomatic CPPD phenotypes, including osteoarthritis with calcium pyrophosphate (CPP) crystals, acute CPP crystal arthritis, and chronic CPP crystal arthritis. Long-term use of medications for CPPD treatment (>3 months during the year preceding the visit) was recorded in all patients. Physical examination included assessment of tender and swollen joints and determination of the frequency of exacerbations during the calendar year. Results and discussion . The study included 218 patients with CPPD (mean age 61.7±11.1 years), of whom 133 (61%) were women. For longterm control of disease manifestations, 149 (68.3%) patients received one or more drugs, including colchicine (n=87, 39.9%), nonsteroidal antiinflammatory drugs (NSAIDs; n=38, 17.4%), methotrexate (n=31, 14.2%), hydroxychloroquine (n=30, 13.7%), and glucocorticoids (n=16, 7.3%). Thirty nine patients (17.9%) used two of these drugs on a long-term basis, and 7 (3.2%) used three. Patients who did not receive longterm treatment used NSAIDs episodically more often than those in the long-term treatment group (n=30, 43.5% and n=26, 17.5%, respectively; pConclusion. Most patients with symptomatic CPPD phenotypes require long-term therapy to control disease symptoms. Colchicine is the most widely used drug regardless of the CPPD phenotype.

  • Open Access

    Prospects for the use of new antidiabetic drugs in rheumatology

    by E. L. Nasonov, M. V. Shestakova, L. V. Kondratyeva, M. S. Eliseev, Е. Л. Насонов, М. В. Шестакова, Л. В. Кондратьева, М. С. Елисеев

    In the spectrum of comorbid pathology in rheumatic and musculoskeletal diseases (RMD), metabolic disorders attract special attention, primarily obesity, associated with an increased risk of developing autoimmune diseases, including RMD, in the population. In rheumatology, the problem of using antidiabetic drugs that reduce the risk of obesity is considered not only from the point of view of treating type 2 diabetes mellitus (T2DM), but also as a broader problem associated with the prospects of repositioning, defined as a strategy for finding new medical indications for existing, approved for use or studied drugs, which is especially important for the harmonization of therapy for complex RMD. In recent years, new classes of drugs have been developed for the treatment of T2DM and its complications: glucagon-like peptide 1 receptor agonists (GLP1-RAs), and sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors; gliflozins). Along with the classical antidiabetic effects, GLP-1RAs and SGLT-2 inhibitors have a wide range of anti-inflammatory and immunomodulatory mechanisms of action, which can potentiate the effectiveness of anti-inflammatory therapy for RMD and inhibit the development of comorbid pathology. The article discusses data regarding the mechanisms of anti-inflammatory activity of antidiabetic drugs and their effectiveness in RMD. However, in order to determine the true place of these drugs in relation to the personalization of RMD therapy, primarily in reducing the risk of various comorbid pathologies, further studies are needed aimed at directly comparing the effectiveness of drugs in various clinical scenarios.


  • Is calcium pyrophosphate crystal deposition disease a new disease in the list of rheumatic diseases with cardiovascular risk?

    by M. S. Eliseev, M. N. Chikina, Ya. I. Kuzmina, E. L. Nasonov

    Calcium pyrophosphate deposition disease (CPPD) is a disease associated with inflammation at the sites of deposition of calcium pyrophosphate crystals, is at the same time one of the most widespread and least well-studied rheumatic diseases. Among the most pressing issues is the possibility of CPPD influencing the risk of cardiovascular diseases (CVDs) and mortality. The suspected causes contributing to the development of CVDs include microcrystalline inflammation and pathological vascular calcification, due to the common mechanisms of articular and vascular calcification. These assumptions are supported by data from several cross-sectional studies that have shown an independent direct association of CPPD with CVDs outcomes, but without the influence of CPPD on cardiovascular mortality. It is possible that the lack of association of CPPD with cardiovascular mortality with a high frequency of cardiovascular events at the same time is explained by the intake of colchicine, as well as the physiological anti-infective effects of interleukin 1. It is important to further search for mechanisms linking CPPD with CVDs and therapy aimed at preventing CVDs in this disease.


  • Drug therapy for CPPD in real clinical practice

    by M. S. Eliseev, M. N. Chikina, Yа. I. Kuzmina

    According to the recommendations of the ELUAR expert committee, the choice of drug therapy for calcium pyrophosphate deposition disease (CPPD) is based on the clinical presentation (phenotype) of the disease. However, it is unknown whether this approach is implemented in real clinical practice. The aim of the study was to analyze the frequency of use of drugs prescribed for the treatment of CPPD in various phenotypes of the disease. Materials and methods . A total of 266 patients with CPPD over 18 years of age with clinical symptoms were examined. These patients were divided into phenotypes: recurrent acute arthritis, chronic arthritis, and osteoarthritis (OA) with calcium pyrophosphate (CPP) crystals. The frequency of prescription of colchicine, methotrexate, hydroxychloroquine, glucocorticoids (GCs), and nonsteroidal anti-inflammatory drugs (NSAIDs) was compared. Results . Based on phenotyping results, the group of patients with acute arthritis consisted of 40 patients (15 %), chronic arthritis – 157 (59 %), and OA with PFK crystals – 69 (26 %). The frequency of medications used to treat CPPD in all study participants (n=266): 207 patients (77.8 %) received NSAIDs, 97 (36.5 %) colchicine, 46 (17.3 %) hydroxychloroquine, 60 (22.6 %) methotrexate, and 34 (12.8 %) GCs. In acute arthritis, 30 patients (75 %) received NSAIDs, 5 (12.5 %) GCs, 17 (42.5 %) colchicine, 4 (10 %) hydroxychloroquine, and 8 (20 %) methotrexate. Patients with chronic arthritis: 123 (78.3 %) NSAIDs, 21 (13.4 %) – GCs, 58 (36.9 %) – colchicine, 29 (18.5 %) – hydroxychloroquine, 40 (25.5 %) – methotrexate. Patients with OA with CPP crystals: 54 (78.3 %) – NSAIDs, 8 (11.6 %) – GCs, 22 (31.9 %) – colchicine, 13 (18.8 %) – hydroxychloroquine, 12 (17.4 %) – methotrexate. Conclusions . The most commonly used medications for CPPD are NSAIDs and colchicine, with no significant differences in the frequency of prescription of individual medications across different disease phenotypes. The use of low-dose colchicine in CPPD appears to be the most appropriate.

  • Open Access

    Febuxostat: new opportunities and prospects for use

    by M. S. Eliseev, Ya. I. Kuzmina

    Фебуксостат: новые возможности и перспективы применения

  • Efficacy and Safety of Long-term Administration of Various Doses of Colchicine in Patients with Gout

    by M. S. Eliseev, M. N. Chikina, Y. I. Kuzmina, E. V. Panina, E. L. Nasonov

    To compare the efficacy and safety of different doses of colchicine (0.5 mg/day vs. 1.0 mg/day) used for the prevention of arthritis attacks in gout patients during the initiation of urate-lowering therapy. —The study included 96 patients diagnosed with gout. Patients were randomized into three groups: those receiving colchicine 0.5 mg/day, those receiving colchicine 1 mg/day, and those without anti-inflammatory therapy. All participants were prescribed febuxostat 80 mg/day. The duration of the observation period was 6 months. The frequency and severity of arthritis attacks, as well as the incidence of adverse events, were compared. —Patients who did not receive colchicine experienced arthritis attacks more frequently compared to those receiving colchicine 0.5 mg/day (p = 0.03) and 1 mg/day (p = 0.007). In the groups receiving colchicine 0.5 and 1.0 mg/day, the frequency of attacks did not differ significantly (p = 0.6), nor did the proportion of patients who did not experience arthritis attacks (18 (56%) and 22 (69%), respectively, p = 0.3). Among the patients not taking colchicine, 9 (28%) did not develop arthritis attacks (p = 0.02 compared to those taking 0.5 mg/day and p = 0.001 for 1 mg/day). The administration of colchicine 1 mg/day (but not 0.5 mg/day) was associated with lower pain intensity on the visual analog scale (VAS) during arthritis attacks compared to the non-therapy group (p = 0.04). The frequency of adverse events was comparable across the groups. —The use of colchicine 0.5 mg/day for the prevention of arthritis attacks in gout patients is justified due to the absence of differences in efficacy compared to the higher dose. However, prescribing colchicine 1 mg/day also demonstrates a good safety profile and may be considered for the prevention of arthritis attacks.


  • Open Access

    Xanthoma simulating gouty tophus (case report of atypical cholesterol crystal deposition)

    by Maxim Sergeevich Eliseev, Yanina Igorevna Kuzmina, Maria Nikolaevna Chikina

    The most common clinical manifestation of hyperlipidemia is the formation of xanthomas, which are most often localized subcutaneously, sometimes involving tendons and ligaments, and are usually asymptomatic. A fairly rare manifestation of hyperlipidemia is hypercholesterolemic arthritis caused by cholesterol crystals. In this article, we present a case of atypical xanthoma formation in a patient in the area of the first metatarsophalangeal joint, which resembled a gouty tophus. Taking into account the presence of hyperuricemia in the blood and the “classic” lesion of the first metatarsophalangeal joint, gout was primarily suspected in the patient. The diagnosis of arthritis associated with cholesterol crystals was confirmed using the “gold standard” diagnosis of microcrystalline arthritis—crystal detection using polarization microscopy. This case gives a clear idea of how important it is not to rely solely on the clinical picture when diagnosing gout.

  • How to use the new clinical guidelines “Idiopathic gout”: principles of urate-lowering therapy

    by M. S. Eliseev, Ya. I. Kuzmina, M. N. Chikina

    In 2025, new clinical guidelines on gout – one of the most common rheumatic diseases – were published. This article discusses the main principles of the practical application of the key component of successful gout management: urate-lowering therapy (ULT). Special attention is given to the indications for initiating ULT, the timing of its initiation and duration, and the principles for selecting the optimal target serum uric acid (UA) level. The most rational regimens for prescribing allopurinol and febuxostat are examined, taking into account, in accordance with the guidelines, the clinical manifestations of gout and the presence of comorbidities. Other medicinal agents that affect serum UA levels are also presented.

  • Safety of colchicine use in clinical practice: illusions and reality

    by M. N. Chikina, M. S. Eliseev, Ya. I. Kuzmina

    Colchicine – an alkaloid isolated from the corms of Colchicum autumnale – is a potent pharmacological agent used in the treatment of various conditions. Its clinical efficacy, confirmed by numerous studies, raises no doubts within the scientific community. Nevertheless, despite the proven therapeutic properties of colchicine, its safety remains surrounded by myths and prejudices. In this work, we attempted to refute these myths, relying on modern scientific data and methodological approaches.